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ABSTRACT
Introduction: Pain is a major symptom in
many medical conditions which can be
relieved thanks to analgesics. The goal of this
work was to present an indirect comparison of
efficacy and tolerability profiles of two
analgesics, tramadol and tapentadol, in
patients with chronic non-malignant pain.
Methods: In the absence of a head-to-head
comparison between these two opioid drugs,
model-based meta-analyses were used to
characterize the pain intensity time dynamics
and evaluate the proportions of most frequent
adverse events (constipation, nausea, vomiting,
dizziness, and somnolence) and drop-outs (due
to adverse event, as well as due to lack of
efficacy) in each treatment group. Using these
models, the investigational treatments were
compared on the basis of Monte Carlo
simulation outcomes.
Results: Data were extracted from 45 Phase II
and Phase III studies representing a total of 81
treatment arms, i.e., approximately 13,000
patients. The pain intensity model shows, that
after having adjusted for differences in baseline
pain intensity and placebo effects, tramadol
300 mg once daily (qd) was slightly more
effective in reducing pain than tapentadol
100–250 mg twice daily (bid), with a 46%
change from baseline for the former versus
36% for the latter. From a tolerability
standpoint, both drugs showed, as expected,
increased risks of adverse events compared to
placebo. Yet, tapentadol was associated with
slightly lower risks of constipation, and nausea
than tramadol.
Conclusion: Overall, the analysis showed that
the benefit–risk profiles of tramadol 300 mg qd
and tapentadol 100–250 mg bid were
approximately even. The amount of data to
characterize dose–response relationships was
sufficient only in the tramadol group; public
access to tapentadol efficacy and tolerability
readouts across a wide dose range in chronic
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non-malignant pain would allow a comparison
of therapeutic indices, a straight quantitation of
the benefit–risk ratio. Knowing that their side-
effects have been identified as potential
hindrance to prescription, a broad and open
access to clinical trial data in this indication is
encouraged in order to facilitate the evaluation
of the opiate analgesics clinical utility.
Keywords: Adverse events; Chronic pain;
Clinical utility; Drop-outs; Meta-analysis;
Non-linear mixed-effect model; Tapentadol;
Tramadol; Pain intensity
INTRODUCTION
Non-malignant chronic pain affects up to 20%
of the population of Western countries [1–3].
Chronic pain can originate from a variety of
underlying diseases or syndromes, such as
cancer, lower back pain, musculoskeletal
alteration, or neuropathy. Opioid agonists are
normally used to treat this condition. However,
strong pain killers come with an array of side-
effects that substantially narrow their
therapeutic window. Opioid prescription has
dramatically increased over the past 10 years,
inducing risks of overdose, particularly for
patients with chronic pain. Clinical practice
guidelines have recently been reviewed and
mitigation strategies have been thoroughly
discussed in a recent appraisal [4]. Given these
drug attributes, opioids are often titrated to an
individual-based optimal efficacy–tolerability
ratio. Even then, a considerable amount of
adverse events can remain at the cost of
reduced efficacy. In the current study, the
efficacy and safety profiles of two major
opioids, tramadol and tapentadol, are
compared using model-based quantitative
methods. A review of the mechanism of action
of tramadol and tapentadol can be found in a
study by Nossaman et al. [5]. Tramadol is a
centrally acting synthetic analgesic of the
opioid class used to treat moderate-to-severe
pain. Tramadol and its active metabolite
produce anti-nociception predominantly via a
mechanism of binding to mu-opioid receptors.
Appropriate dosing regimen and compliance are
critical to the success of the therapy. Belonging
to the same class of analgesic, tapentadol was
approved more recently (in 2008) for the relief
of moderate-to-severe acute pain in patients
18 years or older. Tapentadol binds to mu-
opioid receptors and inhibits norepinephrine
re-uptake. These two processes are thought to be
responsible for pain relief with tapentadol [5].
Although tapentadol is often presented as a
new-generation analgesic, no formal head-to-
head comparison between tramadol and
tapentadol has been run and/or made public
so far.
Summary-level information about clinical
efficacy (pain intensity) for these treatments
can be found in the literature. It can be
extracted and combined into a meta-analysis
framework to compare treatment effects of
different drugs across different patient
populations. Frequently, the assessment of the
efficacy of a compound in meta-analyses is
based on the end of study results only and
pain scores collected at repeated times points
are discarded or are averaged. However, study
durations can be different, which makes the
interpretation of findings ambiguous if the time
dynamics are not explicitly covered in the
meta-analysis. Incorporating longitudinal
information about pain intensity would allow
the evaluation of the onset of effect, its
magnitude, and its resilience, and could
provide accurate estimates of the true response
and, as a consequence, more valid comparison
between treatments. Longitudinal model-based
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meta-analyses are an extension of traditional
meta-analyses and represent a framework for
assessment of such longitudinal information.
Two important components are captured in
these models: the magnitude of the treatment
effect which may be related to the dose in a
linear or non-linear way, and its time course.
Longitudinal model-based meta-analyses have
been reported for migraine pain [6], Alzheimer’s
disease [7], and type 2 diabetes mellitus [8],
while Ahn and French [9] discuss some
methodological aspects of this approach.
Gastrointestinal adverse effects, dizziness,
and somnolence are among the most
commonly reported adverse events in patients
taking opioids analgesics [10]. The frequency of
these adverse events has been discussed in
previous meta-analyses [11, 12], but they were
based on a small number of studies and did not
take into account the possible confounding
effects of dose or study duration. In the
present work, the authors apply meta-analysis
techniques to compare the proportion of
patients experiencing constipation, nausea,
vomiting, dizziness, and/or somnolence (at
least once during the study), in the four
treatment groups, respectively, while
accounting for dose, study duration, and any
other relevant covariate effect. In addition, the
same analysis is applied to the frequency of
patient withdrawals, either due to adverse
events or due to lack of efficacy.
The key objective of the present study was to
compare the benefit–risk tradeoff of tramadol
versus tapentadol in patients with chronic non-
malignant pain by leveraging public-domain
summary-level data and performing indirect
treatment comparisons. The results of this
analysis are presented in the light of previous
meta-analyses and provide evidence, or
highlight a lack of it, for differentiation
between the investigated compounds.
METHODS
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Literature Data
A systematic screening of clinical trials
involving tramadol and/or tapentadol for the
treatment of non-malignant pain was
performed. Clinical trials published until
November 2011, were considered. The search
sources included PubMed/MEDLINETM,
European Medicines Agency, and Food and
Drug Administration drug labeling
information and additional sources were
identified in clinical trial registries. Several
combinations of key words were used (see the
Electronic Supplementary Material for details).
A total of 83 sources were identified. Leaving
out the sources which did not report any data
on pain intensity or adverse event frequency or
drop-out rate, and after full-text examination,
publications describing 45 unique double-blind
Phase II or Phase III randomized clinical trials in
adult patients with chronic non-malignant pain
were retained in the meta-analysis. A list of the
trials used in the analysis with key information
is provided in Supplementary Table S1 in the
Electronic Supplementary Material.
The majority of the trials were placebo-
controlled. Six tapentadol trials [13–18] were
active-controlled trials, using oxycodone as
comparator. Because these trials were large in
size, hence informative, it was important to
keep them in the analysis. In case of active-
controlled trials with a comparator other than
tramadol or tapentadol, only the arm
corresponding to one of these two treatments
was retained in the analysis dataset. The list of
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studies retained in the analysis is presented in
Supplementary Table S1 in the Electronic
Supplementary Material. It is also worth
mentioning that three studies (Adler et al.
[19], Mongin et al. [20] and Beaulieu et al.
[21]) considered tramadol at several therapeutic
doses and in various formulations without a
placebo arm. For each treatment arm,
information about patient population, sample
size, baseline and demographic characteristics
were also available.
In addition to describing the treatment effect
over time, other differences among trials and
treatment arms due to intrinsic (e.g., disease
severity, gender, age) or extrinsic factors (e.g.,
concomitant medication) were accounted for in
the analysis. These factors are introduced in the
model as covariates. However, because patient-
specific covariates are in the form of summary
statistics, their values cover a narrower range
than the individual values. Consequently, they
are less informative about their effects unless
the data have been stratified based on them.
Covariates of interest in the dataset included
year of publication, baseline pain intensity,
pain syndrome, and trial duration. The various
pain syndromes were grouped into the
following categories: osteoarthritis pain, back
pain, neuropathic pain, and other chronic non-
malignant pain.
Pain Intensity
Pain intensity was analyzed on a scale ranging
from 0 to 10 (0 = no pain, 10 = worst
imaginable pain). Where efficacy was reported
only in terms of change from baseline, the
absolute pain intensity score was derived from
the difference between change from baseline
and baseline values. Pain intensity data from
papers which failed to report baseline pain were
discarded. Because the scales used to measure
pain intensity were very heterogeneous, two
broad categories were considered to capture the
residual variability in the model: visual analog
scale (VAS; continuous) and categorical scales.
The rules used to convert the raw data into a
0–10 range are presented in Table 1.
Graphical exploration of the data revealed a
marked placebo response across studies (Fig. 1).
The placebo effect in pain treatment is a well-
known phenomenon [22] which was taken into
account in the model development by
capturing not only the pain intensity time
course in the active treatment groups, but also
in the placebo group. Capturing the precise
time dynamics in the placebo groups was also
important because the indirect comparison of
treatments relies on a common (exchangeable)
placebo response.
Table 1 Conversion rules for each pain intensity scale
Scale (x) Conversion rule
(-)1–4 Likert scale 10 9 (x ? 1)/5
(-)3 to (?)3 scale 10 9 (x ? 3)/6
0–10 none
0–3 (4-point) categorical 10 9 (x/3)
0–4 (5-point) categorical score 10 9 (x/4)
1–5 (5-point) categorical Likert scale 10 9 (x - 1)/4
11-point numeric None
16-point numeric 10 9 x/15
BS11 None
VAS (-)10 to (?)10 cm 10 9 (x ? 10)/20
VAS 0–100 mm x/10
NAS 0–100 mm x/10
VAS 0–10 cm None
VAS 0–2,400 mm x/240
VAS 0–500 mm x/50
BS11 11-point box score, NAS numerical analog scale,
VAS visual analog scale
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The proposed structural model (1) for the kth
pain intensity measured in the jth treatment
arm of trial i, at time t included three
components: (i) a baseline term (Base); (ii) the
placebo and drug effects time courses, and (iii)
the between-study random effects and residual
error terms. The model was written as follows:
PIijk ¼ g Baseij þ Rij  1  ektijk
 þ eijk
 
g xf g ¼ 10  exp xð Þ
1 þ exp xð Þ
ð1Þ
In this equation, Baseij is the baseline
estimate (or intercept); Rij corresponds to the
placebo or drug effect, reflecting the change
from baseline; and eijk represents the residual
(unexplained) variability. The exploratory
graphical analysis showed a mono-exponential
decrease of the response over time (in all
treatment groups including placebo), which
was parameterized in the model by the decay
rate k. In order to estimate the respective effect
size and time course, separate R and separate k
parameters were introduced in the model for
each drug (placebo, tramadol, and tapentadol).
The decay rate was parameterized such that:
kdrug = kpbo ? kDdrug.
In order to estimate the between-study
variability, random effects were associated
additively with the Base parameter and
exponentially with the R parameter:
Baseij ¼ Base þ gBaseij with gBaseij N 0; x2Base
 
Rij ¼ R  egRij with gRij N 0; x2R
 
In order to acknowledge our confidence in
trials executed in larger populations, the
residual error was entered in the model as
inversely proportional to the number of
patients (N) contributing to each data point.






Fig. 1 Pain intensity (normalized to a 0–10 scale) over
time, in patients treated for chronic non-malignant pain,
with placebo, tapentadol, or tramadol. Each circle represents
the arm-level average score, with a diameter proportional to
the sample size in the arm. The outer curves give the 95%
predictive interval and the bold curve the predicted median,
using the ﬁnal pain intensity model
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As mentioned above, the residual variance
was different whether the scale used to measure
pain intensity was continuous (VAS) or
categorical. These variances are hereafter
referred to as r1
2 and r2
2, instead of a unique rres
2 .
The model was coded in R using the nlme
function of package nlme [23]. This function
fitted the non-linear mixed-effect model by the
method of maximum likelihood.
Adverse Events and Drop-outs
The tolerability-related events (adverse events
and drop-outs) were analyzed in terms of
number of patients experiencing the event (at
least once) during the treatment period. Using
the same notation as above, the number of
patients experiencing event E (at least once) was
assumed to follow a binomial distribution with
a probability pEij, and a sample size Nij, such
that:
Eij Bin pEij; Nij
 
:
The probability of a patient having an event
in treatment arm j of trial i was modeled using a
logistic model, as afunction of the intercept (a0)
and the m covariates (Xmij), including drug
(parameterized either as a factor or as a dose–
response relationship), and other covariates.
A term for between-treatment variability (uij),
assumed to be normally distributed in the logit









uij N 0; x2E
 
:
This model evaluates the log odds of the
outcome (E) probability on various predictors.
Hence, the parameter bm measures the effect of
increasing Xmij by one unit on the log odds
ratio.
When enough data were available the dose–
response relationship was investigated using
linear model. Non-linear dose–response
relationships were discarded a priori based on
observed trends in exploratory graphics.
The potential for an increased risk of an
adverse event under treatment seemed likely
to be related to treatment duration; the
alternative would be to hypothesize a one-off
risk increase on treatment initiation, with no
additional risk thereafter, however long the
treatment was applied. Hence, treatment
duration was always tested as a covariate in
the tolerability events and drop-out rates meta-
analyses.
The model was coded in R using the glmer
function of package lme4 [24]. This function
fitted the linear model by the method of
maximum likelihood.
Model Selection
During the model development phase, a cut-off
of 4-points in Akaike Information Criterion
value was used to decide which model to
retain. Goodness-of-fit plots and visual
predicted checks (VPC) inform the decision of
whether to consider the model appropriate for
simulations or not. Goodness-of-fit plots
included plots of observed versus predicted,
and observed versus individual predicted values,
stratified (as appropriate) by drug, to ensure
adequacy of the fit across drugs.
To obtain a VPC, the observations of the
analysis dataset are simulated 1,000 times using
the fitted model (structure, parameter estimates,
and associated uncertainty). The distribution of
the model predictions are superimposed onto
the actual trial data to obtain a visual display of
the model ability to describe the data it is
coming from.
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Indirect Comparison of Tramadol
and Tapentadol
Particular attention was devoted to the
comparison of tramadol and tapentadol
benefit–risk ratios. In absence of clinical trial
results providing head-to-head comparison
between these two compounds, an adjusted
indirect comparison method is considered.
Given the non-linear form (in the
parameters) of the pain intensity time course
model, tramadol and tapentadol were compared
by simulation of typical time profiles. For this
purpose, the typical tramadol dose was
considered to be 300 mg qd, and the typical
duration of a trial, 12 weeks. A total of 2,000
treatment arms (1,000 per group) each
containing 1,000 patients were simulated, with
a baseline pain intensity of 7 out of 10. The
predicted differences in mean pain intensity
between tramadol and tapentadol group for
each trial were then summarized by the median,
and 95% predictive interval.
For the comparison of event proportion, the
Butcher’s [25] indirect treatment comparison
method was readily applied to derive the odds-




The analysis database consisted of 45 unique
trial reports, representing publicly available
(yet not free) knowledge gathered from
12,985 patients. The distribution of
treatment arms per indication is provided in
Table 2. The treatments evaluated were
approximately equally distributed across pain
syndromes.
The mean (SD) duration of follow-up of the
studies was 9.0 (6.8) weeks, with one trial
exceeding 15 weeks, i.e., Wild et al. [16],
which had a 52-week duration. Only the trial
discussed by Wild et al. [16] was open-label; the
others were double-blind, randomized
controlled trials. The median age in these
trials was 58 years (range 47–72 years), and
64% of participants were female. The
treatment duration in case of osteoarthritis or
back pain (median 12 weeks) was longer than
the one in patients experiencing neuropathic
(median 9 weeks) or other unspecific types of
pain (median 4 weeks). The total number of
observations available to fit the pain intensity
model was 534.
Incidences of adverse events or drop-out
rates were frequently, but not consistently,
reported across trials. While the drop-out rate
due to adverse event was available for each of
the 45 trials contained in the meta-database,
the other types of events were reported less
frequently: constipation and nausea frequencies
were reported in 40 articles, dizziness in 36,
drop-out due to lack of efficacy in 37, vomiting
in 31, and somnolence in 31. Whatever the
event, the range of proportion of patients
experiencing it was consistently large,
reflecting the heterogeneity between trials and
possibly between pain syndromes considered in
this analysis. The most frequent adverse events
were constipation and nausea, observed in up to
40% of patients exposed to tramadol, and
dizziness, observed in 52% of the patients
exposed to tramadol in study by Norrbrink
and Lundeberg [26].
Pain Intensity
The mean baseline pain intensity across studies
was equal to 6.9 (SD = 0.72), with no marked
differences between pain symptoms categories,
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nor between treatment group. The decline in
pain intensity in the placebo groups on a 0–10
scale is displayed in Fig. 1(left panel). Without
the resort of a statistical model it would be very
difficult to estimate the active treatments effect
sizes and associated uncertainties.
The model (1) was fitted to the data. With
the final model (of which the parameter
estimates are presented in Table 3), no obvious
misspecification was found based on the
goodness-of-fit plots. The visual predictive
checks displayed in Fig. 1 were satisfying. The
placebo effect was modeled as a mono-
exponential function of time, with a decay
rate (k) equal to 0.571 week-1, corresponding to
a time to reach 50% of the maximum effect
(t1/2) equal to 1.2 weeks. The onset of effect was
found to be as fast in the active groups
(tapentadol and tramadol) as in placebo.
As observed previously [27], subjects with
high baseline pain intensity (PI0i) had a greater
reduction in pain intensity than subjects with
low baseline scores. This phenomenon
materialized in our model into a positive and
significant hBase parameter estimate. In addition,
for patients treated with tramadol, the extent of
reduction was related to dose (Dose) by an Emax
function. Due to lack of data, it was not possible
to capture the dose–response relationship for
tapentadol. However, patients treated with
tapentadol received doses ranging between 100
and 250 mg twice daily (bid). This dose range
constitutes the domain of validity of our results.
The extent of reduction Rij in model (1) was
therefore expressed as:









Assuming a baseline pain intensity level of
6.9 on a scale ranging from 0 to 10, this model
revealed that, in a typical trial, tramadol 300 mg
qd would lead to a 46% (95% CI 41–51%)
reduction of the pain intensity compared to
baseline. The estimated reduction with
tapentadol 100 to 250 mg bid would be equal
Table 2 Number of treatment arms per syndrome
Osteoarthritis pain Back pain Neuropathic pain Miscellaneousa
Placebo 17 7 4 2
Tapentadol 5 2 1 0
Tramadol 30 7 2 4
Total 52 (63.2%) 16 (22.6%) 7 (8.5%) 6 (5.7%)
a Lee et al. [33]—rheumatoid arthritis pain; Beaulieu et al. [19]—chronic non-cancer pain; Bennett et al. [34]—
ﬁbromyalgia pain
Table 3 Parameter estimates of the ﬁnal pain intensity
model
Parameter Estimate (SE) x
Base 0.812 (0.053) 0.313




k (1/week) 0.571 (0.015)
ED50 (mg) 184 (66)
r1 0.260
r2 0.205
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to 36% (95% CI 35–37%), while placebo
treatment would trigger a 28% (95% CI
23–33%) reduction in pain intensity compared
to baseline.
The Monte Carlo simulations run to
compare tramadol (300 mg qd) and tapentadol
(100–250 mg bid), assuming a fixed baseline
value of 6.9 (on a 0–10 pain intensity range),
showed that at week 12 the pain intensity
would be 0.69 points lower in the tramadol
(300 mg qd) group compared to the tapentadol
(100–250 mg bid) group. This difference was
statistically significant, as illustrated in Fig. 2,
yet not clinically relevant.
Adverse Events and Drop-outs
Event rates were higher for opioids than placebo
for all events, with the exception withdrawal
due to lack of efficacy, when placebo was higher
than opioids. During the model building
process, trial duration and type of pain
syndrome covariates did not prove to be worth
keeping in the final logistic models applied to
adverse events frequencies. Hence, models with
different intercepts between treatments were
used to describe the data. Only for constipation
could the slope of a linear and positive dose-
dependency be estimated in patients treated
with tramadol.
The model parameter estimates (and
associated uncertainty) converted in odds-
ratio, using placebo as a reference, are
presented in Fig. 3. These results confirm the
high frequency of adverse events associated
with opioid-based therapies. Due to the large
number of treatment arms contributing to this
analysis, the precision of the estimate is
relatively good.
The indirect comparison of odds-ratios
between tramadol (300 mg qd) and tapentadol
(100–250 mg bid) show a significantly higher
risk of experiencing constipation and vomiting
when patients are treated with tramadol, and a
slightly higher risk of dizziness when patients
are treated with tapentadol (Fig. 3).
The analysis of drop-out frequencies shows
expected differences between treatment groups
(Fig. 4): more drop-out due to adverse events
(DO.AE) in the active treatment compared to
placebo, and more drop-out due to lack of
efficacy (DO.LoE) in the placebo group. In both
models (for DO.AE and DO.LoE), a dose-
dependent relationship could be captured in
the tramadol group. Patients treated with
higher doses of tramadol were more prone to
adverse events and less prone to dropping out
for lack of efficacy. Dose coverage on tapentadol
were insufficient to allow capturing of these
trends in these treatment groups.
DISCUSSION
Quantitative assessment of the efficacy and
tolerability of treatments in pain was
performed across different therapeutic and
patient populations. The group-level results of
48 clinical trials in osteoarthritis, back pain,
Fig. 2 Distribution of 1,000 differences in predicted
group-level pain intensity (normalized to a 0–10 scale)
after 12 weeks of treatment with tramadol (300 mg one
daily) versus tapentadol (100–250 mg twice daily) (DPI).
Predictions of pain intensity were simulated from the ﬁnal
model, assuming 1,000 patients per arm. The plain and
dashed vertical lines materialize the median and 95%
prediction interval, respectively
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neuropathic pain, or other chronic non-
malignant pain were pooled together. As
expected, the reduction of pain intensity on
placebo treatment was large and clinically
important [28], imposing the medication
under investigation in the active arm to have
a very large effect in order to differentiate from
placebo. Assuming a baseline score of 6.9 (on a
0–10 range), the mean pain intensity in placebo
groups at week 12, was found to be 4.8, i.e., a
reduction of 2.1 points.
Based on the data currently available in the
literature, the comparison of tramadol versus
tapentadol efficacy indicated that the most
effective treatment is tramadol (300 mg qd)
with a median pain intensity score reduced
from 6.9 at baseline (on a 0–10 range) to 3.7
after 12 weeks of treatment. For the same
baseline value, the reduction estimated for
patients treated with tapentadol (100–250 mg
bid) led to a median score of 4.3, at week 12.
The full time course of pain intensity was
modeled, which allowed the assessment of the
onset of effect for each compound. It was
estimated that 50% of the maximal effect
could be reached within 8 days after treatment
initiation, whatever the treatment was
(including placebo). The only significant
covariate retained in the final
pharmacodynamic model was the baseline
pain intensity; the higher the pain score at
baseline, the larger the extent of effect on
Fig. 3 From left to right number of arms (Narms), frequency
of adverse event, odds-ratio (with 95% conﬁdence interval)
for the active groups versus placebo and odds-ratio (with
95% conﬁdence interval) for tramadol (300 mg once daily)
versus tapentadol (100–250 mg twice daily), for each type
of adverse event (Constip. constipation, Dizzin. dizziness,
Somnol. somnolence)
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treatment. This expected relationship [24] was
observed in both active and placebo groups. The
time dynamics were not significantly different
across indications (osteoarthritic pain, back
pain, neuropathic pain, or others), nor did the
study duration influence the studies outcomes.
With respect to the tolerability profile, the
results of the current review were consistent
with the ones reported in a previous meta-
analysis [11] as illustrated in Supplementary
Table S2 in the Electronic Supplementary
Material.
In past analyses [11, 12], the variety of opioid
drugs included (with different doses, different
dosing schedules, different comparators, and in
different conditions) meant that no statistical
analysis was possible. Hence, no quantitative,
formal conclusion could be drawn. Many of the
publicly available results at that time referred to
small and short-term trials, so that the risk of
erroneous, incomplete, or imprecise
conclusions from heterogeneous data was
high. Since 2005, knowledge and data have
increased in size and in nature. The access to a
significant number of trials offers new
perspectives to understand and evaluate the
benefit–risk profile of analgesics in chronic non-
malignant pain. Model-based meta-analysis
techniques allow for controlling and
measuring the variability in response that
come from differences in dose, time under
treatment, and baseline characteristics. The
mathematical framework not only gives the
possibility to summarize the information in a
clear and concise way, but also to predict the
response in various hypothetical clinical
scenarios. Hence, quantitative knowledge
about competitor efficacy can be helpful when
setting the desired safety and efficacy profile of
a new drug candidate in pain management.
The majority of the studies included in this
review were funded by the pharmaceutical
industry. As recently discussed by Dunn et al.
[29], the research agenda of the pharmaceutical
industry may introduce a bias in the quality of
results reported in the literature. In particular,
less than adequate reporting of adverse events
information in clinical trials is relatively
common. While frequency was the only
available data according to our review of the
Fig. 4 From left to right number of arms (Narms),
proportion of drop-out patients, odds-ratio (with 95%
conﬁdence interval) for the active groups versus placebo,
and odds-ratio (with 95% conﬁdence interval) for tramadol
(300 mg once daily) versus tapentadol (100–25/0 mg twice
daily), per reason of withdrawal (DO.AE, drop-out due to
adverse event; or DO.LoE, drop-out due to lack of efﬁcacy)
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public-domain literature, it would be more
informative to study incidence rates (number
of event per unit time) of events or the time to
(repeated) events. Patients starting opioids are
usually told to expect initial adverse events,
such as nausea and drowsiness, but that these
will improve rapidly. Judging the adverse event
time profile in the absence of longitudinal data
analysis is unlikely to be sufficient to support
such statements. Several authors have discussed
the value of such data for a better benefit–risk
assessment of new therapeutic treatment [30,
31].
The current method does not overcome the
general weaknesses of many other meta-
analyses, such as publication bias, mixed
quality of the included studies, and their
different strategies for selecting study subjects,
obtaining exposure and outcome information,
or controlling for potential confounders.
Besides, the trials were not designed to study
primarily the adverse events and drop-out rates,
hence the results of the corresponding meta-
analysis should be considered as hypothesis-
generating. However, methods are now
available to compare pairs of treatment, in
absence of data from direct head-to-head
comparisons [32]. While the work we
presented was focusing on the comparison of
two opioids, the same modeling framework
could be used to expand this analysis to an
entire network of treatments.
CONCLUSION
The meta-analysis suggests that the benefit–risk
ratios of tramadol (300 mg qd)and tapentadol
(100–250 mg bid) are similar or not markedly
different, with a slightly larger efficacy for
tramadol and a slightly better safety profile in
favor of tapentadol. In spite of a clinical
meaningful efficacy, information from large
numbers of patients exposed to these opiate
analgesics confirms that one in five patients will
discontinue the treatment due to intolerable
adverse events, most likely constipation or
nausea. As with any meta-analysis, the
conclusions must be treated with a degree of
caution.
The presented framework can easily be
adapted and re-used to address questions
related to the development and prescription of
pain management drugs. As more competitor
information becomes available, the literature
database can be extended and the modeling
framework can be updated to include most
recent information. Such a longitudinal model-
based meta-analysis can also represent a
valuable tool for health authorities who want
to evaluate new drug applications.
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